Peringkat dalam Saham
#15446
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Kapitalisasi Pasar
$355.41M
Perubahan (1 hari)
-0.63%
Perubahan (1 tahun)
91.48%
Perdagangan BioAge Labs Inc. (BIOA)
Harga BIOA dengan kapitalisasi pasar B
Kapitalisasi pasar dari BioAge Labs Inc.(BIOA)
Kapitalisasi Pasar: $355.41M
Per September 2026, BioAge Labs Inc. memiliki kapitalisasi pasar sebesar $355.41M. Ini menjadikan BioAge Labs Inc. sebagai perusahaan 15446th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar BioAge Labs Inc. dari 2024 hingga 2026
BIOA dibandingkan dengan 5 teratas stocks paling populer
| Harga BIOA |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.226T
|
+1,470,351.76%
|
|
|
|
|
$4.713T
|
+1,325,889.19%
|
|
|
|
|
$4.034T
|
+1,134,843.41%
|
|
|
|
|
$3.738T
|
+1,051,558.11%
|
|
|
|
|
$2.744T
|
+772,071.50%
|
